1. Home
  2. FRPT vs CDNA Comparison

FRPT vs CDNA Comparison

Compare FRPT & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshpet Inc.

FRPT

Freshpet Inc.

N/A

Current Price

$67.29

Market Cap

3.0B

ML Signal

N/A

Logo CareDx Inc.

CDNA

CareDx Inc.

N/A

Current Price

$86.47

Market Cap

3.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRPT
CDNA
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.3B
IPO Year
2014
2007

Fundamental Metrics

Financial Performance
Metric
FRPT
CDNA
Price
$67.29
$86.47
Analyst Decision
Buy
Buy
Analyst Count
18
7
Target Price
★ $83.19
$65.33
AVG Volume (30 Days)
935.5K
★ 1.3M
Earning Date
11-04-2026
10-29-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 183.87
N/A
EPS
1.29
★ 2.45
Revenue
★ $1,102,015,000.00
$48,324,000.00
Revenue This Year
$11.37
$30.36
Revenue Next Year
$8.49
$6.23
P/E Ratio
$51.25
★ $33.32
Revenue Growth
13.01
★ 18.93
52 Week Low
$46.45
$14.27
52 Week High
$86.00
$73.43

Technical Indicators

Market Signals
Indicator
FRPT
CDNA
Relative Strength Index (RSI) 56.89 80.69
Support Level $66.32 $17.30
Resistance Level $68.77 N/A
Average True Range (ATR) 2.32 4.65
MACD 0.14 0.93
Stochastic Oscillator 65.66 86.08

Price Performance

Historical Comparison
FRPT
CDNA

About FRPT Freshpet Inc.

Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (likely representing well north of 90% of sales), with cats and treats nascent contributors. Geographically, the company's home US market, where all its food is produced, accounts for nearly all of sales, with exports to Canada, the United Kingdom, and other European countries being very small contributors.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: